• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Icon acquires Aptiv Solutions to strengthen adaptive design capabilities

Icon acquires Aptiv Solutions to strengthen adaptive design capabilities

March 31, 2014
CenterWatch Staff

Seeking to enhance its capabilities in the design and execution of portfolio-wide adaptive clinical trials for pharmaceutical, biotech and medical device companies, Icon has agreed to acquire Aptiv Solutions, a global services company focused on enhancing clinical trial decision-making, for $143.5 million in cash.

In acquiring Aptiv, based in Reston, Va., Icon will enhance its software product support for the design, simulation and analysis of adaptive trials. Aptiv’s software also is used by the FDA and regulators in Europe and Japan.

“Icon is the perfect fit,” said Pat Donnelly, chairman and CEO of Aptiv Solutions. “With the globalization of clinical trials and our existing capabilities, we needed to quickly get into Latin America, parts of Asia and other marketplaces. Our deal with Icon enables us to fulfill our strategy. For them, they get leading adaptive design expertise and decision-making capabilities moving into phase II rather than waiting for pivotal phase III trials.  And there is almost zero client overlap.”

Donnelly said the two companies began acquisition talks last fall about how the two might fit together, but did not discuss the economics of the deal until December. He noted both companies have a shared focus on innovation that will position the combined entity as “the go-to service provider for design and execution of adaptive trials for drug, diagnostic and medical companies in a fast-growing marketplace.”

For Icon, the Aptiv acquisition provides added experience in the management of medical device trials, leveraging its adaptive capabilities and regulatory expertise to expedite the development of a wide range of medical devices. Aptiv’s software, called ADDPLAN,  is used by  more than 50 large pharmaceutical and medical device companies and  academic researchers.

Icon also gains Aptiv’s recently formed consortium of major drug companies collaboratively developing new statistical methodologies for the design of innovative dose-finding clinical trials, with an emphasis on adaptive designs. The co-founding companies are Novartis Pharma, Janssen Pharmaceuticals and Eli Lilly.

Nuala Murphy, president, Icon Clinical Research Services, said Aptiv’s adaptive trial capabilities “will further differentiate and enhance our services to help our customers identify the most promising drug candidates earlier. Their presence in Japan will also broaden our existing capabilities in this market.”

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing